You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 8,252,776


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,252,776 protect, and when does it expire?

Patent 8,252,776 protects XIMINO and SOLODYN and is included in two NDAs.

This patent has twelve patent family members in nine countries.

Summary for Patent: 8,252,776
Title:Minocycline oral dosage forms for the treatment of acne
Abstract: Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne.
Inventor(s): Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Briscoe, TX), Bhatia; Kuljit (Nesconset, NY), Patel; Bhiku (Chandler, AZ)
Assignee: Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:11/695,513
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,252,776
Patent Claim Types:
see list of patent claims
Use; Dosage form; Composition;
Patent landscape, scope, and claims:

United States Patent 8,252,776: A Detailed Analysis of Scope and Claims

Overview of the Patent

United States Patent 8,252,776, titled "Minocycline oral dosage forms for the treatment of acne," is a patent that covers specific oral dosage forms of minocycline, a tetracycline-class antibiotic. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Patent Background

Publication and Authority

The patent was published on August 28, 2012, and is assigned to the United States. It is based on the patent application US11/695,513, filed on April 3, 2007[2].

Scope of the Patent

Invention Description

The patent describes oral dosage forms of minocycline, particularly focusing on controlled-release formulations. These dosage forms are designed to treat acne and other skin conditions effectively while minimizing side effects. The invention includes various compositions and methods for preparing these dosage forms, ensuring a sustained release of the antibiotic over a specified period[2].

Key Components

  • Dosage Form: The patent details different types of oral dosage forms, including tablets, capsules, and other solid oral formulations.
  • Controlled Release: The controlled-release aspect is crucial, as it ensures that the minocycline is released in a manner that maintains therapeutic levels over an extended period.
  • Excipients and Formulation: The patent lists various excipients and materials used in the formulation, such as hydroxypropyl methyl cellulose, silicon oxide, and purified water[2].

Claims of the Patent

Independent and Dependent Claims

The patent includes several independent and dependent claims that define the scope of the invention.

  • Independent Claims: These claims outline the broadest aspects of the invention, such as the composition of the oral dosage form and the method of preparing it.
  • Dependent Claims: These claims are narrower and specify particular embodiments or variations of the invention, including specific excipients, release profiles, and manufacturing processes[2].

Claim Language and Scope

The claim language is critical in defining the patent's scope. For instance, the claims specify the type of minocycline used, the dosage form, and the release characteristics. This specificity helps in distinguishing the invention from prior art and ensures that the patent covers a unique and novel contribution to the field[3].

Patent Landscape

Prior Art and Related Patents

To understand the patent landscape, it is essential to consider prior art and related patents. The USPTO's Patent Public Search tool and other international databases can be used to identify similar patents and applications. For example, searching through the European Patent Office's esp@cenet or the World Intellectual Property Organization's PATENTSCOPE can reveal related inventions in the field of oral antibiotic formulations[1].

Global Dossier and International Filings

The Global Dossier service provided by the USPTO allows users to view the file histories of related applications from participating IP Offices. This can help in identifying whether similar patents have been filed in other jurisdictions, which is crucial for understanding the global patent landscape for minocycline oral dosage forms[1].

Litigation and Enforcement

Patent Quality and Scope

The quality and scope of patent claims can significantly impact litigation and enforcement. Research has shown that narrower claims at publication are associated with a higher probability of grant and a shorter examination process. Broader claims, on the other hand, may face more scrutiny and potential challenges during the examination process and in litigation[3].

Industry Impact

The patent's impact on the industry can be substantial. For instance, the exclusive rights granted by this patent can influence the development and marketing of similar minocycline formulations by other companies. This can lead to licensing agreements or litigation if other entities attempt to produce similar products without permission[3].

Examples and Case Studies

Pearl's Dental AI Patents

While not directly related to minocycline, the example of Pearl's dental AI patents illustrates how companies can build a robust patent portfolio to protect their innovations. Pearl's patents on machine learning techniques for dental practice data analysis demonstrate the importance of intellectual property in the healthcare and technology sectors[4].

Key Takeaways

  • Specificity in Claims: The patent's claims are detailed and specific, ensuring that the invention is clearly distinguished from prior art.
  • Controlled Release: The controlled-release aspect of the minocycline dosage forms is a key innovation, providing therapeutic benefits over an extended period.
  • Global Landscape: Understanding the global patent landscape through tools like the Global Dossier is crucial for managing intellectual property rights internationally.
  • Litigation and Enforcement: The scope and quality of patent claims can significantly affect the patent's enforceability and potential litigation outcomes.

FAQs

Q: What is the main focus of United States Patent 8,252,776?

A: The main focus is on oral dosage forms of minocycline, particularly controlled-release formulations for treating acne.

Q: How can one search for related patents internationally?

A: Using databases like the European Patent Office's esp@cenet, the World Intellectual Property Organization's PATENTSCOPE, and the USPTO's Global Dossier service.

Q: What is the significance of claim language in patent scope?

A: Claim language defines the scope of the invention, distinguishing it from prior art and ensuring the patent covers a unique contribution.

Q: How does the patent's scope affect its enforceability?

A: Narrower claims at publication are associated with a higher probability of grant and shorter examination processes, while broader claims may face more scrutiny and potential challenges.

Q: What tools can be used to analyze the patent landscape?

A: Tools like the USPTO's Patent Public Search, Global Dossier, and international patent databases such as PATENTSCOPE and esp@cenet.

Sources

  1. USPTO - Search for patents: https://www.uspto.gov/patents/search
  2. Google Patents - Minocycline oral dosage forms for the treatment of acne: https://patents.google.com/patent/US8252776B2/en
  3. Hoover Institution - Patent Claims and Patent Scope: https://www.hoover.org/sites/default/files/ip2-wp16001-paper.pdf
  4. HelloPearl - Pearl Granted U.S. Patent for Dental Practice Data Analysis AI Technology: https://www.hellopearl.com/press-release/pearl-granted-u-s-patent-for-dental-practice-data-analysis-ai-technology

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 8,252,776

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 DISCN No No ⤷  Subscribe ⤷  Subscribe TREATMENT OF ACNE ⤷  Subscribe
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 DISCN No No ⤷  Subscribe ⤷  Subscribe TREATMENT OF ACNE ⤷  Subscribe
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 DISCN No No ⤷  Subscribe ⤷  Subscribe TREATMENT OF ACNE ⤷  Subscribe
Bausch SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-001 May 8, 2006 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF ACNE ⤷  Subscribe
Bausch SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-008 Aug 27, 2010 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF ACNE ⤷  Subscribe
Bausch SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-004 Jul 23, 2009 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF ACNE ⤷  Subscribe
Bausch SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-007 Aug 27, 2010 DISCN Yes No ⤷  Subscribe ⤷  Subscribe TREATMENT OF ACNE ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,252,776

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2006262428 ⤷  Subscribe
Canada 2613273 ⤷  Subscribe
China 101208097 ⤷  Subscribe
European Patent Office 1898925 ⤷  Subscribe
Japan 2008543936 ⤷  Subscribe
Japan 2013213047 ⤷  Subscribe
Japan 5744976 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.